Interferon News and Research

RSS
Wake-up call to physicians caring for hepatitis B patients

Wake-up call to physicians caring for hepatitis B patients

A cure for Hepatitis C using existing treatments

A cure for Hepatitis C using existing treatments

Cure for hepatitis C

Cure for hepatitis C

Peregrine Pharmaceuticals to initiate new Bavituximab HCV trial

Peregrine Pharmaceuticals to initiate new Bavituximab HCV trial

Herpes infection may be symbiotic

Herpes infection may be symbiotic

Dealing with emerging diseases

Dealing with emerging diseases

Researchers identify immune dysfunction in melanoma patients

Researchers identify immune dysfunction in melanoma patients

Green tea shows potential for HIV-associated dementia prevention

Green tea shows potential for HIV-associated dementia prevention

Cellular protein found that interferes with hepatitis C virus replication

Cellular protein found that interferes with hepatitis C virus replication

New test for liver disease

New test for liver disease

Liver center leading record number of studies to tackle hepatitis C

Liver center leading record number of studies to tackle hepatitis C

Viragen announces European Multiferon licensing agreement

Viragen announces European Multiferon licensing agreement

Researchers identify key gene that may be a marker of breast cancer metastasis

Researchers identify key gene that may be a marker of breast cancer metastasis

Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses

Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

MS patients not receiving medications to slow disease progression

MS patients not receiving medications to slow disease progression

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences reports results of phase 2b trial of Albuferon

New drug therapy zaps hepatitis C in 12 weeks

New drug therapy zaps hepatitis C in 12 weeks

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.